Treatment of Irritable bowel syndrome with unani medicine

To evaluate the comparative efficacy of Sufoof Inderjao Talkh with Jawarish Shahi in the management of Zalq al-Ama (irritable Bowel Syndrome-Diarrhea predominant)–An open label randomized clinical trial - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066685

Enrollment

Registered

2024-05-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Sufoof Inderjao Talkh: Sufoof Inderjao Talkh Dose- 3gm in divided dose in capsule form Each capsule- 500mg Frequency- 3 capsule BID Route of administration- Orally Duration- 45 days Con

Eligibility

Inclusion criteria

Inclusion criteria: Subjects fulfill the Rome ? diagnostic criteria (for IBS-D) 1.Subjects between 18-50 years of age. 2.Subjects of either gender. 3.Subjects who sign the written consent form and agree for follow up.

Exclusion criteria

Exclusion criteria: 1.Diagnosed cases of HTN, DM, Malignancy, Cerebrovascular disease, PVD, Renal disease, Liver disease. 2.Diagnosed cases of IBD, Peptic ulcer disease, Intestinal tuberculosis. 3.Hb less than 9 gm/dl, AST, ALT greater than120 IU/L, S. creatinine greater than1.5 mg/dl, occult blood in stool. 4.Pregnancy and lactation. 5.Red flags sign

Design outcomes

Primary

Measure	Time frame
IBS Severity Scoring Scale (IBS-SSS)Timepoint: at baseline, 15th, 30th, and 45th days.	—

Secondary

Measure	Time frame
Change in different clinical symptoms of IBS-DTimepoint: 45 Days	—

Countries

India

Contacts

Public ContactDr Md Shafat Karim

Govt Tibbi College and Hospital

dr.md.najibur.rahman@gmail.com7004484257

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026